PPIDT00103
Drug Information
| Name | Panitumumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB01269 |
| Type | biotech |
| Indication | For the treatment of EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Intravenous |
200 mg/10mL
|
| Injection, solution, concentrate | Intravenous |
20 mg/ml
|
| Injection, solution, concentrate | Intravenous; Parenteral |
20 MG/ML
|
| Solution | Intravenous |
100 mg/5mL
|
| Solution | Intravenous |
100 mg / 5 mL
|
| Solution | Intravenous |
200 mg / 10 mL
|
| Solution | Intravenous |
400 mg / 20 mL
|
| Solution | Intravenous |
400 mg/20mL
|
| Solution | Parenteral |
400.000 mg
|
| Injection, solution | Intravenous |
100 mg
|
| Injection, solution, concentrate | Intravenous |
100 mg
|
| Injection, solution | Intravenous |
20 mg/mL
|
| Solution | Intravenous |
100 mg
|
| Solution, concentrate | Intravenous |
2000000 mg
|
| Injection, solution, concentrate | Intravenous |
100 mg/5ml
|